White House Intensifies Push for ‘Most Favored Nation’ Drug Pricing

WASHINGTON — The Biden administration is facing renewed resistance from Capitol Hill as it attempts to advance a policy aimed at lowering prescription drug costs by tying U.S. Prices to those paid in other countries – a concept known as “most-favored nation” (MFN) pricing. While President Trump initially championed this approach during his second term, the current effort to codify it into law is encountering skepticism from both sides of the aisle, raising questions about its feasibility and potential impact on the pharmaceutical industry and patient access to medications.

The core idea behind MFN pricing is straightforward: the U.S. Currently pays significantly more for many prescription drugs than other developed nations. The administration argues that by aligning U.S. Prices with the lowest prices paid elsewhere, substantial savings could be achieved. However, critics contend that such a policy could stifle pharmaceutical innovation, limit patient access to new drugs, and potentially lead to supply disruptions.

A History of MFN Proposals and Political Hurdles

The concept of MFN pricing isn’t new. During his second term, President Trump made lowering drug prices a central tenet of his healthcare agenda. He issued an executive order in November 2020 directing the Department of Health and Human Services (HHS) to finalize a rule implementing MFN pricing for certain Medicare Part B drugs. However, that rule faced legal challenges and was ultimately withdrawn by the Biden administration.

Now, the Biden administration is attempting to revive the MFN concept through legislation. According to two Trump administration officials briefed on the conversations, the White House is actively lobbying Republicans on Capitol Hill to include MFN provisions in a broader healthcare package. However, lawmakers have expressed concerns that the policy represents government overreach and interferes with free-market principles. This resistance echoes similar arguments made during the Trump administration, highlighting the deep-seated ideological divisions surrounding drug pricing reform.

How MFN Pricing Would Work and Potential Impacts

The proposed MFN rule, as initially outlined during the Trump administration, would have required drug manufacturers to charge Medicare Part B the same prices for certain drugs that they charge in a basket of other developed countries, including those in the Organisation for Economic Co-operation and Development (OECD). The Kaiser Family Foundation (KFF) provides a detailed timeline of these policy actions, noting the numerous challenges and revisions the rule underwent.

Proponents argue that MFN pricing could lead to significant savings for Medicare and, potentially, for all Americans. The Congressional Budget Office (CBO) estimated that the original MFN rule could have saved Medicare billions of dollars over a decade. However, the pharmaceutical industry has vehemently opposed the policy, arguing that it would reduce their revenues and discourage investment in research and development. They contend that lower prices in other countries reflect different market conditions, such as government price controls and single-payer healthcare systems, and that simply importing those prices to the U.S. Would be detrimental to innovation.

The Role of Pharmaceutical Innovation and Access

A central concern surrounding MFN pricing is its potential impact on pharmaceutical innovation. The pharmaceutical industry argues that the high prices they charge in the U.S. Are necessary to fund the costly and risky process of developing new drugs. They warn that if their revenues are significantly reduced, they may be forced to cut back on research and development, leading to fewer new treatments for diseases like cancer, Alzheimer’s, and HIV/AIDS.

However, critics of the industry argue that pharmaceutical companies already generate substantial profits and that there is little evidence to suggest that lower prices would necessarily stifle innovation. They point to the fact that many new drugs are developed with significant public funding from the National Institutes of Health (NIH) and other government agencies. They also argue that the industry spends a disproportionate amount of money on marketing and advertising rather than research and development.

Current Congressional Stance and Future Outlook

As of March 2026, the prospects for MFN pricing legislation appear uncertain. Republicans on Capitol Hill remain largely opposed to the policy, viewing it as government interference in the market. While some Democrats may be supportive, there is also concern about the potential impact on pharmaceutical innovation. The White House will likely require to make concessions and address these concerns in order to garner sufficient support for the legislation.

The debate over MFN pricing is part of a broader conversation about drug pricing reform in the U.S. Other proposals under consideration include allowing Medicare to negotiate drug prices directly with manufacturers, importing drugs from Canada, and capping out-of-pocket costs for seniors. The outcome of these debates will have significant implications for the pharmaceutical industry, patients, and the future of healthcare in the U.S.

What Comes Next: Navigating the Legislative Process

The path forward for MFN pricing legislation is complex and uncertain. Several key steps must occur for the policy to become law. First, the administration must continue to negotiate with lawmakers from both parties to build a consensus around a compromise proposal. This may involve making concessions on the scope of the policy, the drugs covered, and the implementation timeline. Second, the legislation must be passed by both the House of Representatives and the Senate. This will require overcoming potential procedural hurdles and securing enough votes to overcome any potential filibusters. Finally, the legislation must be signed into law by the President.

Even if MFN pricing legislation is enacted, it is likely to face legal challenges from the pharmaceutical industry. These challenges could delay or even block the implementation of the policy. The administration will need to be prepared to defend its legal authority to implement MFN pricing and to address any concerns raised by the courts. The White House website details President Trump’s previous efforts and provides context for the current debate.